Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $884.50 -1.05 (-0.12%) 6:20 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $884.50 -1.05 (-0.12%) 6:20 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
Lilly (LLY) Q2 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) reports mixed Q2 results. Total revenues in the quarter hurt by the coronavirus pandemic
Eli Lilly (LLY) Q2 Earnings Top Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 19.62% and -2.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Spectacular Earnings Charts
by Tracey Ryniec
These 5 stocks are breaking out to new 5-year highs heading into their earnings reports. Can they keep that momentum?
Big Drug Stock Q2 Earnings on Jul 30: LLY, GILD, VRTX & More
by Kinjel Shah
Let us take a look at five big drug/biotech companies, GILD, LLY, VRTX, ALXN, and AZN, gearing up for their earnings release.
How Hard Will Coronavirus Hit Lilly's (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports second-quarter earnings.
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.
3 Strong Dividend Stocks to Buy Now for Income & Coronavirus Growth
by Benjamin Rains
Let's dive into three stocks that are projected to grow during the pandemic that also provide solid income through dividends...
Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $167.04, marking a +0.65% move from the previous day.
Lilly's Plaque Psoriasis Candidate Meets Phase III Study Goals
by Zacks Equity Research
Lilly's (LLY) autoimmune disorder candidate, mirikizumab, superior to Cosentyx in a phase III study for patients with moderate-to-severe plaque psoriasis.
AstraZeneca's Farxiga Gets Fast Track Tag for New Indication
by Zacks Equity Research
AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.
Zacks.com featured highlights include: BJ's Wholesale Club, Eli Lilly, Sprouts Farmers Market, Kroger and Everbridge
by Zacks Equity Research
Zacks.com featured highlights include: BJ's Wholesale Club, Eli Lilly, Sprouts Farmers Market, Kroger and Everbridge
J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance
by Zacks Equity Research
J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.
Glaxo's Multiple Myeloma Candidate Gets FDA Committee Nod
by Zacks Equity Research
Glaxo's (GSK) belantamab mafodotin gets FDA's Oncologic Drugs Advisory Committee votes as its benefits outweigh risks for relapsed/refractory multiple myeloma patients.
5 Low-Beta Stocks to Beat Coronavirus-Induced Volatility
by Nilanjan Banerjee
To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $163.88 in the latest trading session, marking a +1.11% move from the prior day.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.
FDA Aims to Fast-Track Coronavirus Vaccine: 3 Stocks in Focus
by Ritujay Ghosh
Vaccine seems to be the only hope now to counter the pandemic given that millions of new cases of coronavirus are being reported every day.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Bayer's Drug Meets Primary Endpoint in Renal Outcomes Study
by Zacks Equity Research
Bayer's (BAYRY) investigational candidate, finerenone, meets primary endpoint in the phase III FIDELIO_DKD study in patients with CKD and T2D.
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
by Kinjel Shah
Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $169.13, moving +1.43% from the previous trading session.
Regeneron Initiates Studies on Experimental Coronavirus Drug
by Zacks Equity Research
Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.